



Pauciflorines A and B, Novel Melanin Biosynthesis Inhibitors from *Kopsia*

Toh-Seok Kam*, K. Yoganathan, Takashi Koyano^a and Kanki Komiyama^b

Department of Chemistry, University of Malaya, 59100 Kuala Lumpur, Malaysia.

^aTerumo Corporation, Ashigarakami-gun, Kanagawa 259-01 Japan.

^bThe Kitasato Institute, 5-9-1 Shirokane, Minato-ku, Tokyo 108.


Abstract : Two new pentacyclic indoles viz., Pauciflorines A and B from *Kopsia pauciflora* were found to exhibit potent inhibitory activity on melanin biosynthesis of cultured B-16 melanoma cells.
Copyright © 1996 Elsevier Science Ltd

The Malaysian members of the genus *Kopsia* have yielded a prodigious harvest of new natural products possessing novel carbon skeletons as well as useful bioactivities¹⁻³. We would like to report the structure and novel bioactivity of two new indoles viz., pauciflorine A **1** and B **2**, isolated from the ethanol extract of the leaves of *Kopsia pauciflora* Hook. f. (Apocynaceae), a species native to North Borneo, which have been found to be potent inhibitors of melanin biosynthesis.


Pauciflorine A⁴ and pauciflorine B⁵ were obtained from the leaves of *Kopsia pauciflora* in yields of 0.22 g Kg⁻¹ and 0.03 g Kg⁻¹ respectively. Pauciflorine A **1**, was obtained in amorphous form, [α]_D - 50.7° (CHCl₃, *c* 2.0)⁵. The EIMS of pauciflorine A showed a molecular ion at *m/z* 470 (C₂₄H₂₆N₂O₈, 80%) with other significant fragments at 452 (15%, M - H₂O), 438 (100%, M - OMe - H), 411 (20%, M - CO₂Me) and 394 (15%, M - CO₂Me - OH). The UV spectrum showed absorption maxima at 227, 248, 283 and 293 nm which indicate the presence of a dihydroindole chromophore. The ¹³C NMR spectrum showed a total of 24 carbon resonances in agreement with the molecular formula deduced from the mass spectrum. The ¹H and ¹³C NMR spectral data (Table 1) showed the presence of a methylenedioxy substituent at carbon-11 and 12 (a pair of aromatic AB doublets at δ_H 6.43 & 6.59 and another pair at δ_H 5.85, 5.97, δ_C 100.5), a CO₂Me substituent at N₁ (δ_C 156.9), an ester function at carbon-16 (δ_C 173.1), a hydroxyl function at carbon-16 (δ_H 8.43), a

lactam carbonyl at carbon-21 (δ_C 174.9) and a trisubstituted double bond (δ_H 5.25; δ_C 121.6, 130.3). COSY and HMQC experiments revealed the presence of the following partial structures, *viz.*, an isolated methylene group, a CH₂-CH₂ unit, a CH₂-CH₂-CH₂ unit and a CH=C fragment. This information suggests that the lactam carbonyl should be placed at position 21 since the alternative location of the lactam carbonyl at position 3 or 5 would result in three isolated methylenes in the former case and two CH₂-CH₂ fragments in the latter which was clearly not the case. This would also account for the unusual deshielding observed for H-3 α (δ_H 4.03) as a result of the anisotropy due to the proximate lactam carbonyl function. Finally the placement of the amide carbonyl at position 21 is also supported by the observed 3J correlation between C-21 and H-6 in HMBC. The presence of a β -carbomethoxy function together with an α -OH substituent on carbon-16 is supported by the characteristic carbon NMR shifts which are characteristic of such a substitution pattern in related aspidofractinine-type alkaloids and furthermore this can be confirmed from the observed long range W coupling between the intramolecularly hydrogen-bonded 16-hydroxyl proton and H-17 β as well as from the observed 3J (C-17 to 16-OH) and 2J (C-16 to 16-OH) interactions in HMBC. The molecular formula of pauciflorine yielded a DBE value of 13 and discounting the methylenedioxy function, suggests the presence of a pentacyclic ring system incorporating a trisubstituted double bond. HMBC and NOESY experiments allowed the molecule to be assembled as shown in 1. Key HMBC correlations include the following 3J interactions : C-15 to H-19, C-20 to H-18, C-2 to H-19, C-7 to H-18 and C-16 to H-18. Key NOE interactions include the following : H17 β -H5 β , 16OH-H18 β and H19-H3 α . These observations provide a firm basis for the proposed structure of pauciflorine A and allow the assignment of pauciflorine B as the 11,12-dimethoxy congener of pauciflorine A⁶.

Pauciflorines A and B inhibited melanin synthesis of B16 melanoma cells at a concentration of 13 and 25 $\mu\text{g ml}^{-1}$ respectively without any cytotoxicity towards the cultured cells⁷. This level of inhibition is equivalent to that of the commercial compound, arbutin⁸ and represents a rare example of melanin synthesis inhibition by indole compounds of plant origin.



1



2

Table 1. ^1H and ^{13}C NMR Spectral Data for **1** and **2**^a

Position	1		2	
	δ_{C}	δ_{H}	δ_{C}	δ_{H}
2	82.1	-	83.2	-
3b	42.5	2.91 m	42.6	2.89 m
3a	-	4.03 br t (12.5)	-	4.01 br t (12.5)
5a	44.2	3.27 td (10, 2)	44.5	3.24 brt (10.5)
5b	-	3.66 m	-	3.62 m
6a	30.1	1.99 m	29.9	2.00 m
6b	-	2.61 ddd (16, 9, 2)	-	2.86 m
7	60.1	-	60.5	-
8	130.0	-	129.5	-
9	117.3	6.43 d (7.8)	119.2	6.64 d (8.3)
10	104.9	6.59 d (7.8)	108.8	6.67 d (8.3)
11	148.4	-	152.7	-
12	134.3	-	138.3	-
13	124.4	-	134.8	-
14a	21.5	1.51 br d (14.6)	21.7	1.50 br d (14.6)
14b	-	2.05 m	-	2.06 m
15a	35.7	2.24 m	35.7	2.22m
15b	-	2.24 m	-	2.22 m
16	75.3	-	75.4	-
17a	36.8	2.44 br d (19.5)	37.1	2.47 br d (19.5)
17b	-	2.85 br d (19.5)	-	2.84 br d (19.5)
18a	30.9	2.71 dd (16.6, 6.4)	32.1	2.67 dd (16.6, 6.4)
18b	-	3.07 d (16.6)	-	3.04 d (16.6)
19	121.6	5.25 d (6.4)	121.6	5.22 d (6.4)
20	130.3	-	130.2	-
21	174.9	-	175.3	-
16-OH	-	8.43 d (2)	-	8.03 d (2)
OCH ₂ O	100.5	5.97 d (1.5); 5.85 d (1.5)	-	-
NCO ₂ Me	53.5	3.88 s	53.8	3.84 s
NCO ₂ Me	156.9	-	158.4	-
CO ₂ Me	52.7	3.80 s	52.5	3.79 s
CO ₂ Me	173.1	-	173.2	-
11-OMe	-	-	60.2	3.70 s
12-OMe	-	-	56.1	3.84 s

^a CDCl₃, 270 MHz; assignments based on COSY, HMQC, HMBC and NOESY.

Acknowledgements : We would like to thank the University of Malaya and IRPA for financial support, Dr. Wong Khoon Meng, Leopold Madani and Julius Kulip of the Sabah Forest Department for assistance during the collection of plant material and Dr. C. H. Chuah for some NMR spectra.

References and Notes

1. (a) Kam, T. S., Yoganathan K. and Chuah C. H. *Tetrahedron Lett.*, **1995**, *36*, 759. (b) Kam, T. S., Yoganathan, K. and Chuah, C. H. *Tetrahedron Lett.*, **1994**, *35*, 4457. (c) Kam, T. S., Yoganathan, K. and Chuah, C. H. *Tetrahedron Lett.*, **1993**, *34*, 1819. (d) Kam, T. S., Yoganathan, K., Chuah, C. H. and Chen Wei *Phytochemistry*, **1993**, *32*, 1343. (e) Kam, T. S., Yoganathan, K. and Wong, W. H. *Nat. Prod. Lett.*, **1995**, *5*, 301. (f) Kam, T. S., Tan, P. S., Hoong, P. Y. and Chuah, C. H. *Phytochemistry*, **1993**, *32*, 489. (g) Kam, T. S., Tan, P. S. and Chen Wei. **1993** *Phytochemistry*, *33*, 921. (h) Kam, T. S., Tan, P. S. and Chuah, C. H. *Phytochemistry*, **1992**, *31*, 2936. (i) Kam, T. S. and Tan, P. S. **1990**, *Phytochemistry*, *29*, 2321.
2. Sevenet, T., Allorge, L., David, B., Awang, K., Hadi, A. H. A., Kan-Fan, C., Quirion, J.-C., Remy, F., Schaller, H. and Teo, L. E. *J. Ethnopharmacol.*, **1994**, *41*, 147.
3. Awang, K., Sevenet, T., Pais, M. and Hadi, H. *J. Nat. Prod.*, **1993**, *56*, 1134.
4. Compound **1**, Pauciflorine A, $[\alpha]_D - 50.7^\circ$ (CHCl₃, *c* 2.0). EIMS, *m/z* (rel. int.) : 470 [M⁺, C₂₄H₂₆N₂O₈] (80), 452 (15), 438 (100), 424 (10), 411 (20), 394 (15), 383 (20), 354 (10), 335 (15), 317 (10), 301 (80), 287 (22), 273 (30), 214 (25), 200 (15) and 109 (24). UV (EtOH), λ_{\max} (log ϵ) 227 (4.62), 248 (4.17), 283 (3.14) and 293 (3.02). ¹H and ¹³C NMR : see Table 1.
5. Compound **2**, Pauciflorine B, $[\alpha]_D = -25.0^\circ$ (CHCl₃, *c* 0.4). EIMS, *m/z* (rel. int.) : 486 [M⁺, C₂₅H₃₀N₂O₈] (60), 468 (5), 454 (100), 435 (20), 427 (10), 410 (10), 399 (10), 351 (10), 317 (70), 303 (15), 289 (10), 259 (10), 230 (20) and 109 (12). UV (EtOH), λ_{\max} (log ϵ) 224 (4.49), 253 (3.83), 282 (3.04) and 290 (3.01). ¹H and ¹³C NMR : see Table 1.
6. Ruangrunsi, N., Likhitwitayawuid, K., Jongbunprasert, V., Ponglux, D., Aimi, N., Ogata, K., Yasuoka, M., Haginiwa, J. and Sakai, S. *Tetrahedron Lett.*, **1987**, *28*, 3679.
7. Determination of melanin synthesis inhibition was carried out following a slight modification of previously published procedure : Komiyama, K., Takamatsu, S., Takahashi, Y., Shinose, M., Hayashi, M., Tanaka, H., Iwai, Y. and Omura, S. *J. Antibiotics*, **1993**, *46*, 1520.
8. Shiseido Cosmetics Company, Japan.

(Received in UK 28 May 1996; accepted 14 June 1996)